AbbVie climbs on settlement with makers of generic version of immunology drug

Shares of drugmaker AbbVie ABBV.N rise 5.4% to $223 premarket

Co says it has settled litigation with all manufacturers that filed a marketing application with the U.S. FDA for generic versions of AbbVie's rheumatoid arthritis drug upadacitinib, branded as Rinvoq

As per the agreement, no generic entry for any upadacitinib tablets is expected prior to April 2037 in the United States

Up to last close, stock up 19% YTD